You are here:

pegvisomant (Somavert)

Advice

following a second resubmission considered under the ultra-orphan process:

pegvisomant (Somavert®) is accepted for use within NHS Scotland.

Indication under review: Treatment of adult patients with acromegaly who have had an inadequate response to surgery and / or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 [insulin-like growth factor 1] concentrations or was not tolerated.

In a phase III study, there were significant reductions in IGF-1 levels and improvements in some of the clinical manifestations of acromegaly with pegvisomant compared with placebo.

SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: pegvisomant (Somavert)
SMC Drug ID: 158/05
Manufacturer: Pfizer Ltd
Indication: Treatment of adult patients with acromegaly who have had an inadequate response to surgery and / or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 [insulin-like growth factor 1] concentrations or was not tolerated.
BNF Category:
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 13 November 2017

Archived Advice

Resubmission 5 May 2006
Full submission 9 May 2005

Back